Promises of PAR-1 inhibition in acute coronary syndrome (Q37967451)

26 August 2017

title

Promises of PAR-1 inhibition in acute coronary syndrome (English)

1 reference

26 August 2017

3

Kenneth W Mahaffey

1 reference

26 August 2017

2

Pierluigi Tricoci

1 reference

26 August 2017

1

Sergio Leonardi

1 reference

26 August 2017

publication date

1 February 2012

1 reference

Current cardiology reports

26 August 2017

published in

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

32-39

1 reference

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Aspirin: a historical and contemporary therapeutic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Combination antithrombotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

SCH 602539, a Protease-Activated Receptor-1 Antagonist, Inhibits Thrombosis Alone and in Combination With Cangrelor in a Folts Model of Arterial Thrombosis in Cynomolgus Monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Thrombin signalling and protease-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin Protease-Activated Receptor 1 Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Antiplatelet therapy: thrombin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0232-Z

Effects of ticlopidine, a new platelet aggregation inhibitor in man

21 January 2018

1 reference

12 December 2020

Safety of the Novel Protease-Activated Receptor-1 Antagonist Vorapaxar in Japanese Patients with a History of Ischemic Stroke

1 reference

12 December 2020

The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.

1 reference

12 December 2020

Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats

1 reference

12 December 2020

10.1007/S11886-011-0232-Z

Identifiers

DOI

1 reference

26 August 2017

1 reference